transistor that could have a significant impact on
microchip manufacturing in the semiconductor
industry. The Tyndall junctionless devices have
near ideal electrical properties and behave like the
most perfect transistors, and have the potential
of operating faster while using less energy than
the conventional transistors used in today’s
microprocessors. This means that it hardly suffers at
all from current leakage – the bane of conventional
devices – and so could potentially operate
faster, using less energy. The publication of the
invention of a major new development in transistor
technology in Nature Nanotechnology was a major
accomplishment for the Institute during 2010.
In 2010 Intel Corporation announced details of a 3
year, $1.5million advanced research collaboration
signed with Tyndall. The agreement is the first of
a kind for Intel in Ireland and establishes a direct
collaboration between Tyndall and the heart of
Intel’s technology research group in the US. Intel
has only one other such agreement in Europe.
Under the research agreement Tyndall and Intel
researchers are set to investigate next generation
materials, devices and photonics technologies.
Another idea that could gain traction with Intel is
that photonics could be used for on-chip high-speed
interconnect. The agreement will provide Intel with
a commercial exploitation license to technology
created through the collaboration with Tyndall.
Photonics
The photonics systems group at Tyndall, UCC
is considered amongst the best photonic systems
groups in the world.
Tydall demonstrated a ground-breaking advance
in fibre-to-the-home networks within the EU FP7
PIEMAN project. By increasing the network span
from around 20km, which is typical today, to as
much as 100km, these new networks will potentially
be much simpler and easier to manage with
significantly lower equipment and operational costs.
Health
The Royal College of Surgeons in Ireland (RCSI)
Colles Institute and Tyndall combined their
respective strengths, synergies in ICT design
hardware, clinical trial and market validation
through the signing of a Memorandum of
Understanding (MOU) in April 2010. This MOU
facilitates the full set of building blocks which allow
an idea to be taken from concept right through to
ICT design, to pre-clinical, clinical trial to market
realisation. The collaboration is a national initiative
which encourages both academia and industry from
Ireland and internationally to access the combined
infrastructure.
The RCSI Colles Institute -Tyndall collaboration
will provide the structure to develop technology
solutions for the global biomedical device and
surgical markets. Translating research, development
and innovation into commercialised products will
fuel Ireland’s economic growth. Tyndall and RCSI
Colles Institute clearly understand that Ireland
needs to make its own opportunities, create its own
jobs and companies, if we are to sustain economic
recovery.
Tyndall has a number of leading capabilities in
health, spanning Wireless Sensors, Diagnostics,
71